- Fee assured
- Verified this account
I underwent general training in clinical & laboratory haematology in the West Midlands and the Bristol/Bath area. In the middle of this training, I spent a 3 year period as a Research Fellow developing the use of the polymerase chain reaction to amplify immunoglobulin and T cell receptor genes as a means of assessing minimal residual disease in the bone marrow of children with acute lymphoblastic leukaemia before and after allogeneic stem cell transplantation.
I spend much of my time treating patients with various forms of haematological cancer (i.e. acute leukaemia, lymphoma, Hodgkin's disease, chronic lymphocytic leukaemia and chronic myeloid leukaemia) but I also have a large practice seeing and advising patients on other general haematological conditions (including anaemia, low platelet counts, myeloproliferative disorders and myelodysplasia as well as common coagulation problems).
Since my appointment as a Consultant Haematologist in Bath in January 2000, I was appointed as Clinical Director for Oncology & Haematology at the Royal United Hospital, a post that I held for 10 years until October 2010.
I set up the Oncology & Haematology Clinical Governance Committee in March 2001 and led the group until November 2013 when I was appointed Clinical Governance Lead for the Division of Medicine. I resigned from this latter role in November 2018. However, I now have responsibility for maintaining effective review of patients who have died at the RUH in order to identify and disseminate any learning that may have arisen from the care that they were provided with.
I was elected Chairman of the Avon, Somerset & Wiltshire Cancer Services Haematology Site Specialist Group from December 2001 to July 2006 and still play an active role in the group.
I was a regular member of the South West Regional Cancer Drug Fund Panel from its inception in January 2011 to May 2013.
I am a member of the Panel of Examiners for the Royal College of Pathologists which is responsible for ensuring that trainees in haematology meet the minimum standards to act as a Consultant.
Areas of interest
Haematological Oncology (e.g. leukaemia, lymphoma); Myeloproliferative disorders (e.g. polycythaemia, myelofibrosis, essential thrombocythaemia); Myelodysplasia; Anaemia; Leucopenia; Thrombocytopenia; Thrombosis & anticoagulation
Current NHS consultant posts held
Royal United Hospital Bath NHS Trust (Jan 2000 - present day)
Clinical trials in lymphoma and leukaemia.
British Society for Haematology Young Investigator of the Year award 1996; NHS Clinical Excellence Award level 8 (2018)
11 publications from 1995 - 2001 mainly in the British Journal of Haematology, Blood and the Journal of Clinical Oncology
- MB ChB University of Bristol 1988
- PhD University of Bristol 2000
- MRCP Royal College of Physicians 1991
- MRCPath Royal College of Pathologists 1999
- FRCP Royal College of Physicians 2004
- FRCPath Royal College of Pathologists 2007
Reference number 3355882
Details of entry to specialist register
- CCST, 1999
Affiliations / memberships
British Society for Haematology; American Society of Hematology; British Medical Association; Medical Defence Union
- BMI Bath Clinic
- 08:30 - 14:30
- 01225 838861
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details